Aegerion Pharmaceuticals, Inc. (AEGR) Posts Q2 Loss of 6c/Share; Boosts FY13 Revs Outlook
Tweet Send to a Friend
Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR) reported Q2 EPS of ($0.66), $0.04 worse than the analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
